

Table S1 Patient characteristics (fecal samples)

		Pre-pregnancy	T1	T2	T3	Post-partum
Mean age at diagnosis (y, SD)		22.6 (3.7)				
weeks pregnant at collection (SD)			10.3 (3)	19.7 (3)	31.9 (3.3)	
IBD diagnosis (%)	CD UC	15 (32.6) 31 (67.4)				
Disease location CD (Montreal) (%)	L1 Ileal L2 Colonic L3 Ileocolonic	5 (16.1) 8 (25.8) 18 (58.1)				
Disease behavior CD (Montreal) (%)	B1 non structuring non penetrating B2 Stricturing B3 Penetrating B2+B3 Stricturing and penetrating	23 (74.2) 2 (6.5) 4 (12.9) 2 (6.5)				
Disease extent UC/IBD-U (Montreal) (%)	E1 Proctitis E2 Left-sided colitis E3 Pancolitis	2 (13.3) 7 (46.7) 6 (40)				
Median HBI for CD (IQR)			1 (0-2.5)	0.5 (0-2)	0 (0-2.5)	
Median SCCAI for UC/IBD-U (IQR)			1 (0-4)	1 (0.5-4.5)	1 (0.5-1.5)	
Median disease duration (y, IQR)		5 (2-9)				
IBD maintenance medication (monotherapy)	None 5-ASA Steroids Thiopurine Ani-TNF/anti-integrin	9 (109.6) 7 (15.2) 1 (2.2) 8 (17.4) 13 (28.3)	11 (23.9) 4 (8.7) 1 (2.2) 7 (15.2) 12 (26.1)	11 (23.9) 4 (8.7) 0 7 (15.2) 12 (26.1)	20 (43.5) 4 (8.7) 1 (2.2) 9 (19.6) 4 (8.7)	10 (21.7) 6 (13) 0 7 (15.2) 12 (26.1)
IBD maintenance medication (combination)	Anti-TNF + thiopurine Anti-TNF + thopurine + 5-ASA Anti-TNF + steroids Anti-TNF + steroids + 5-ASA Thiopurine + 5-ASA 5-ASA + steroids	3 (6.5) 0 1 (2.2) 2 (4.3) 2 (4.3) 0	2 (4.3) 2 (4.3) 2 (4.3) 0 3 (6.5) 2 (4.3)	2 (4.3) 2 (4.3) 2 (4.3) 0 3 (6.5) 2 (4.3)	0 1 (2.2) 1 (2.2) 0 3 (6.5) 2 (4.3)	2 (4.3) 2 (4.3) 2 (4.3) 0 3 (6.5) 2 (4.3)
IBD surgery (%)	Bowel resection Perianal surgery Pouch	6 (13) 2 (4.3) 1. (2.2)				

	Appendectomy	1 (2.2)				
Flare (%)		3 (6.5)	5 (10.9)	6 (13)	3 (6.5)	3 (6.5)

CD: Crohn's disease; UC: ulcerative colitis; SD: standard deviation; IQR: interquartile range; y: years; IBD: inflammatory bowel disease; HBI: Harvey Bradshaw index; SCCAI: simple clinical colitis activity index; TNF: tumor necrosis factor; ASA: aminosalicic acid;

Table S2 Patient characteristics (serum samples)

		Pre-pregnancy	T1	T2	T3	Post-partum
Mean age at diagnosis (y, SD)		22.8 (4.9)				
weeks pregnant at collection (SD)			8.4 (2.1)	21.1 (2.6)	32 (3)	
IBD diagnosis (%)	CD UC	8 (24.2) 25 (75.8)				
Disease location CD (Montreal) (%)	L1 Ileal L2 Colonic L3 Ileocolonic	2 (8) 11 (44) 12 (48)				
Disease behavior CD (Montreal) (%)	B1 non structuring non penetrating B2 Stricturing B3 Penetrating B2+B3 Stricturing and penetrating	16 (64) 2 (8) 3 (12) 4 (16)				
Disease extent UC/IBD-U (Montreal) (%)	E1 Proctitis E2 Left-sided colitis E3 Pancolitis	1 (12.5) 3 (37.5) 4 (50)				
Median HBI for CD (IQR)			3 (1-5.5)	1 (0-3.5)	1 (0-2.5)	
Median SCCAI for UC/IBD-U (IQR)			4 (0.505.5)	4 (0-5)	1 (1-2)	
Median disease duration (y, IQR)		6.6 (4.8)				
IBD maintenance medication (monotherapy)	None 5-ASA Thiopurine Ani-TNF/anti-integrin	3 (9.1) 7 (21.1) 3 (9.1) 15 (45.5)	6 (18.2) 5 (15.2) 2 (6.2) 15 (45.5)	6 (18.2) 5 (15.2) 2 (6.1) 16 (48.5)	18 (54.5) 5 (15.2) 3 (9.1) 3 (9.1)	6 (18.2) 5 (15.2) 2 (6.1) 16 (48.5)
IBD maintenance medication (combination)	Anti-TNF + thiopurine Anti-TNF + thopurine + 5-ASA Anti-TNF + steroids Anti-TNF + steroids + 5-ASA Thiopurine + 5-ASA 5-ASA + steroids	1 (3) 2 (6.1) 1 (3) 1 (3) 0 0	1 (3) 1 (3) 1 (3) 0 1 (3) 1 (3)	1 (3) 0 1(3) 0 1 (3) 1 (3)	0 1 (3) 1 (3) 0 1 (3) 1 (3)	2 (3) 0 1 (3) 0 1 (3) 1 (3)
IBD surgery (%)	Bowel resection Perianal surgery Pouch Appendectomy	5 (15.2) 4 (12.1) 1 (3) 0				

Flare (%)		4 (12.1)	6 (18.2)	6 (15.2)	3 (9.1)	2 (6.1)
-----------	--	----------	----------	----------	---------	---------

CD: Crohn's disease; UC: ulcerative colitis; SD: standard deviation; IQR: interquartile range; y: years; IBD: inflammatory bowel disease; HBI: Harvey Bradshaw index; SCCAI: simple clinical colitis activity index; TNF: tumor necrosis factor; ASA: aminosalicic acid;